For the Inventor, By the Inventor

Enter assignee name

Miami, FL, United States of America

Baker Norton Pharmaceuticals, Inc.

USPTO Granted Patents = 24

% Expired Patents = 25.0

Trademarks = 4

Forward Citations = 551

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Samuel Broder (10 out of 10 patents)

Sami Selim (10 out of 10 patents)

Kenneth L Duchin (8 out of 8 patents)

4. Tahir Ahmed (6 out of 9 patents)

5. Phillip Frost (3 out of 13 patents)

6. Frank E Blondino (3 out of 3 patents)

7. Michael Brucato (3 out of 3 patents)

8. Maria W Buenafe (3 out of 3 patents)

9. Elliot F Hahn (2 out of 8 patents)

10. Robert Testman (2 out of 2 patents)

11. Kelly A Cavanaugh (2 out of 2 patents)

12. Janice Louise Cacace (1 out of 50 patents)

13. Gregory L Smith (1 out of 19 patents)

14. Jose Gutierrez-Rocca (1 out of 5 patents)

15. J Michael Rutledge (1 out of 1 patent)

24 patents: Sort by Forward Citations

1. 7056898 - Hypersulfated disaccharides and methods of using the same for the treatment of inflammations (2006-06-06),

2. 7041640 - Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents (2006-05-09),

3. 6964946 - Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same (2005-11-15),

4. 6936583 - Method and compositions for administering taxanes orally to human patients (2005-08-30),

5. 6818615 - Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents (2004-11-16),

6. 6730698 - Method and compositions for administering taxanes orally to human patients (2004-05-04),

7. 6610735 - Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents (2003-08-26),

8. 6451285 - Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant (2002-09-17),

9. 6395770 - Method and compositions for administering taxanes orally to human patients (2002-05-28),

10. 6334445 - Methods and compositions for treatment of ovarian cancer (2002-01-01),

11. 6290930 - Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide (2001-09-18),

12. 6284800 - Methods and compositions for treatment of asthma (2001-09-04),

13. 6245805 - Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents (2001-06-12),

14. 6235725 - Methods and compositions for the prevention of tolerance to medications (2001-05-22),

15. D439325 - Cover for a nasal inhaler (2001-03-21),

Company Overview

Baker Norton Pharmaceuticals, Inc. is a Miami-based company specializing in the development and manufacturing of innovative pharmaceutical products. The organization focuses on creating advanced therapies that address unmet medical needs across various therapeutic areas. With a commitment to research and development, Baker Norton leverages cutting-edge technologies to enhance drug delivery and efficacy, aiming to improve patient outcomes. The company operates within a dynamic regulatory environment, ensuring compliance and quality in its product offerings.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

24 Patents

#33 in Miami, FL

#355 in Florida

#13,884 in US

#26,660 in the World

Miami, FL, United States of America

Baker Norton Pharmaceuticals, Inc.

Forward Citations = 551

26 inventors:

Samuel Broder (10 out of 10 patents)

Sami Selim (10 out of 10 patents)

Kenneth L Duchin (8 out of 8 patents)

4. Tahir Ahmed (6 out of 9 patents)

5. Phillip Frost (3 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Baker Norton Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/baker-norton-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…